Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters

Marina T. Siirin, Amelia P A Travassos Da Rosa, Patrick Newman, Carolyn Weeks-Levy, Beth Ann Coller, Shu Yuan Xiao, Michael M. Lieberman, Douglas M. Watts

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The efficacy of a recombinant subunit West Nile (WN) vaccine candidate was determined in a hamster model of encephalitis. Animals included young, aged, and immunocompromised animals in an effort to simulate key groups at risk of WN virus-induced disease. Groups of aged (12 month old), weanling, and adult hamsters rendered leukopenic after immunization were immunized subcutaneously with a WN virus recombinant envelope protein (WN-80E) with or without WN virus non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. A challenge dose of wild-type WN virus was administered to produce 40-100% mortality in the control hamsters. The recombinant antigen preparations containing WN-80E with or without WN NSl gave similar results. Hamsters in both groups had a strong antibody response after immunization, and none of the aged or weanling animals became ill or developed detectable viremia after challenge with WN virus at 2 weeks after booster vaccination. However, mortality among the control animals (administered adjuvant without antigen) at 2 weeks after booster challenge was 40-60%. In hamsters rendered leukopenic after immunization, survival rates up to 80% were observed, and a low-level viremia was detected in the vaccinated and challenged hamsters. The survival rate was significantly (P < 0.05) higher in animals vaccinated with a higher dose of WN-80E than a lower dose. The addition of NSl did not significantly affect survival after challenge. In contrast, all of the control animals that received adjuvant only developed a very high level of viremia, and the mortality rate was 100%. These findings indicate that the recombinant WN vaccines induced antibody in and afforded protection to young and aged hamsters and immunosuppressed hamsters.

Original languageEnglish (US)
Pages (from-to)955-962
Number of pages8
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume79
Issue number6
StatePublished - Dec 2008

Fingerprint

Mesocricetus
Cricetinae
West Nile virus
Vaccines
Viremia
Immunization
Mortality
Survival Rate
Viral Envelope Proteins
Viral Structural Proteins
Antigens
Virus Diseases
Encephalitis
Recombinant Proteins
Antibody Formation
Vaccination
Antibodies

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Siirin, M. T., Travassos Da Rosa, A. P. A., Newman, P., Weeks-Levy, C., Coller, B. A., Xiao, S. Y., ... Watts, D. M. (2008). Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. American Journal of Tropical Medicine and Hygiene, 79(6), 955-962.

Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. / Siirin, Marina T.; Travassos Da Rosa, Amelia P A; Newman, Patrick; Weeks-Levy, Carolyn; Coller, Beth Ann; Xiao, Shu Yuan; Lieberman, Michael M.; Watts, Douglas M.

In: American Journal of Tropical Medicine and Hygiene, Vol. 79, No. 6, 12.2008, p. 955-962.

Research output: Contribution to journalArticle

Siirin, MT, Travassos Da Rosa, APA, Newman, P, Weeks-Levy, C, Coller, BA, Xiao, SY, Lieberman, MM & Watts, DM 2008, 'Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters', American Journal of Tropical Medicine and Hygiene, vol. 79, no. 6, pp. 955-962.
Siirin MT, Travassos Da Rosa APA, Newman P, Weeks-Levy C, Coller BA, Xiao SY et al. Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. American Journal of Tropical Medicine and Hygiene. 2008 Dec;79(6):955-962.
Siirin, Marina T. ; Travassos Da Rosa, Amelia P A ; Newman, Patrick ; Weeks-Levy, Carolyn ; Coller, Beth Ann ; Xiao, Shu Yuan ; Lieberman, Michael M. ; Watts, Douglas M. / Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. In: American Journal of Tropical Medicine and Hygiene. 2008 ; Vol. 79, No. 6. pp. 955-962.
@article{a34eee14dcb449c2b87226ca318f886e,
title = "Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters",
abstract = "The efficacy of a recombinant subunit West Nile (WN) vaccine candidate was determined in a hamster model of encephalitis. Animals included young, aged, and immunocompromised animals in an effort to simulate key groups at risk of WN virus-induced disease. Groups of aged (12 month old), weanling, and adult hamsters rendered leukopenic after immunization were immunized subcutaneously with a WN virus recombinant envelope protein (WN-80E) with or without WN virus non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. A challenge dose of wild-type WN virus was administered to produce 40-100{\%} mortality in the control hamsters. The recombinant antigen preparations containing WN-80E with or without WN NSl gave similar results. Hamsters in both groups had a strong antibody response after immunization, and none of the aged or weanling animals became ill or developed detectable viremia after challenge with WN virus at 2 weeks after booster vaccination. However, mortality among the control animals (administered adjuvant without antigen) at 2 weeks after booster challenge was 40-60{\%}. In hamsters rendered leukopenic after immunization, survival rates up to 80{\%} were observed, and a low-level viremia was detected in the vaccinated and challenged hamsters. The survival rate was significantly (P < 0.05) higher in animals vaccinated with a higher dose of WN-80E than a lower dose. The addition of NSl did not significantly affect survival after challenge. In contrast, all of the control animals that received adjuvant only developed a very high level of viremia, and the mortality rate was 100{\%}. These findings indicate that the recombinant WN vaccines induced antibody in and afforded protection to young and aged hamsters and immunosuppressed hamsters.",
author = "Siirin, {Marina T.} and {Travassos Da Rosa}, {Amelia P A} and Patrick Newman and Carolyn Weeks-Levy and Coller, {Beth Ann} and Xiao, {Shu Yuan} and Lieberman, {Michael M.} and Watts, {Douglas M.}",
year = "2008",
month = "12",
language = "English (US)",
volume = "79",
pages = "955--962",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "6",

}

TY - JOUR

T1 - Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters

AU - Siirin, Marina T.

AU - Travassos Da Rosa, Amelia P A

AU - Newman, Patrick

AU - Weeks-Levy, Carolyn

AU - Coller, Beth Ann

AU - Xiao, Shu Yuan

AU - Lieberman, Michael M.

AU - Watts, Douglas M.

PY - 2008/12

Y1 - 2008/12

N2 - The efficacy of a recombinant subunit West Nile (WN) vaccine candidate was determined in a hamster model of encephalitis. Animals included young, aged, and immunocompromised animals in an effort to simulate key groups at risk of WN virus-induced disease. Groups of aged (12 month old), weanling, and adult hamsters rendered leukopenic after immunization were immunized subcutaneously with a WN virus recombinant envelope protein (WN-80E) with or without WN virus non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. A challenge dose of wild-type WN virus was administered to produce 40-100% mortality in the control hamsters. The recombinant antigen preparations containing WN-80E with or without WN NSl gave similar results. Hamsters in both groups had a strong antibody response after immunization, and none of the aged or weanling animals became ill or developed detectable viremia after challenge with WN virus at 2 weeks after booster vaccination. However, mortality among the control animals (administered adjuvant without antigen) at 2 weeks after booster challenge was 40-60%. In hamsters rendered leukopenic after immunization, survival rates up to 80% were observed, and a low-level viremia was detected in the vaccinated and challenged hamsters. The survival rate was significantly (P < 0.05) higher in animals vaccinated with a higher dose of WN-80E than a lower dose. The addition of NSl did not significantly affect survival after challenge. In contrast, all of the control animals that received adjuvant only developed a very high level of viremia, and the mortality rate was 100%. These findings indicate that the recombinant WN vaccines induced antibody in and afforded protection to young and aged hamsters and immunosuppressed hamsters.

AB - The efficacy of a recombinant subunit West Nile (WN) vaccine candidate was determined in a hamster model of encephalitis. Animals included young, aged, and immunocompromised animals in an effort to simulate key groups at risk of WN virus-induced disease. Groups of aged (12 month old), weanling, and adult hamsters rendered leukopenic after immunization were immunized subcutaneously with a WN virus recombinant envelope protein (WN-80E) with or without WN virus non-structural protein 1 (NS1) mixed with adjuvant or adjuvant alone. A challenge dose of wild-type WN virus was administered to produce 40-100% mortality in the control hamsters. The recombinant antigen preparations containing WN-80E with or without WN NSl gave similar results. Hamsters in both groups had a strong antibody response after immunization, and none of the aged or weanling animals became ill or developed detectable viremia after challenge with WN virus at 2 weeks after booster vaccination. However, mortality among the control animals (administered adjuvant without antigen) at 2 weeks after booster challenge was 40-60%. In hamsters rendered leukopenic after immunization, survival rates up to 80% were observed, and a low-level viremia was detected in the vaccinated and challenged hamsters. The survival rate was significantly (P < 0.05) higher in animals vaccinated with a higher dose of WN-80E than a lower dose. The addition of NSl did not significantly affect survival after challenge. In contrast, all of the control animals that received adjuvant only developed a very high level of viremia, and the mortality rate was 100%. These findings indicate that the recombinant WN vaccines induced antibody in and afforded protection to young and aged hamsters and immunosuppressed hamsters.

UR - http://www.scopus.com/inward/record.url?scp=57649229390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649229390&partnerID=8YFLogxK

M3 - Article

C2 - 19052311

AN - SCOPUS:57649229390

VL - 79

SP - 955

EP - 962

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 6

ER -